archaelysin family metallopeptidase 1Genealiases: []
Q-omics provides the consensus-scored AMZ1 profile across patient tissues and cancer cell-line models. AMZ1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, AMZ1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, AMZ1 RNA expression shows 16,996 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where AMZ1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AMZ1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AMZ1 survival associations across molecular data types. AMZ1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AMZ1 RNA expression–survival associations across cancer types. High AMZ1 expression shows unfavorable associations in UVM, KICH, MESO, KIRP and OV, but favorable associations in BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for AMZ1 RNA expression.
This table summarizes AMZ1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for AMZ1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AMZ1 shows higher tumor expression in KIRC, HNSC, STAD, COAD, BRCA and KIRP. The KIRC box plot shows higher AMZ1 RNA expression in tumor versus normal tissue (log2 FC = +0.768, t-test p < 0.001).
This table shows molecular features associated with AMZ1 in patient tissues and cancer cell lines. In patient samples, AMZ1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, AMZ1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
